Thelansis

  Antibody-mediated rejection (AMR) is the leading reason for late allograft loss after kidney transplantation. The classification comprises three diagnostic categories for AMR: active AMR, chronic active AMR, and chronic (inactive) AMR. Donor-specific antibodies represent an independent risk factor for AMR and subsequent graft loss. Monitoring AMR treatment responses entails assessing changes in serum creatinine, proteinuria, donor-specific antibodies (DSA) levels, and histopathological findings and exploring potential new approaches. Despite this, there are currently no FDA-approved treatments tailored explicitly for AMR in kidney transplant recipients. Present treatment strategies are based on understanding the pathophysiology of AMR. These approaches often consist of a combination of interventions such as antibody removal, proteasome inhibitors, glucocorticoids, intravenous immunoglobulins (IVIg), anti-CD20 antibodies, and complement blockade. Thelansis’s “Antibody-Mediate...